Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors

NCT02588170 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

219

Enrollment

INDUSTRY

Sponsor class

Conditions

Neuroendocrine Tumors

Interventions

DRUG: Surufatinib
OTHER: Placebo

Sponsor

Hutchison Medipharma Limited